Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera®).
about
Production of lentiviral vectorsTargeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinomaAAV2 delivery of Flt23k intraceptors inhibits murine choroidal neovascularizationStructure of neurotropic adeno-associated virus AAVrh.8.Severe hypertriglyceridemia in Norway: prevalence, clinical and genetic characteristics.AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancerSystemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model.GLP-1-mediated gene therapy approaches for diabetes treatment.Sequence-defined shuttles for targeted nucleic acid and protein delivery.Alipogene tiparvovec: a review of its use in adults with familial lipoprotein lipase deficiency.The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors.Gene therapy and peripheral nerve repair: a perspective.New and improved AAVenues: current status of hemophilia B gene therapy.Plasmodium meets AAV-the (un)likely marriage of parasitology and virology, and how to make the match.Retargeting of herpes simplex virus (HSV) vectors.Adeno-Associated Virus (AAV) as a Vector for Gene Therapy.Blocking sense-strand activity improves potency, safety and specificity of anti-hepatitis B virus short hairpin RNA.Rapid, scalable, and low-cost purification of recombinant adeno-associated virus produced by baculovirus expression vector system.Simple downstream process based on detergent treatment improves yield and in vivo transduction efficacy of adeno-associated virus vectors.A Robust System for Production of Superabundant VP1 Recombinant AAV Vectors.
P2860
Q26750586-CF4F8EFD-FB07-4D17-B965-4F980103EE95Q26772315-8C81AAE3-5073-45F6-885C-3AE2B7CA81A4Q27318539-0872EFEA-3090-4447-8D7C-9E259829050BQ30152836-92BB26B8-8B59-4A54-8DED-32A4B129DED4Q33791924-BCECB577-708A-46E4-BB8C-905131F1BC0CQ35961381-158A7EF2-2810-4061-ACBF-14892F2D193FQ37028654-9D5ADD76-3629-408E-BD21-FD6472840DCDQ38199215-299A26A7-544D-4791-AF59-C9AFD494EF11Q38265619-4294B49E-7B83-451E-BC0E-2DE4E6BA2188Q38307574-E05A816E-3888-4A2A-9F8E-F2E9F7A8FB27Q38388047-23062A40-9383-489C-9B83-5555885043C1Q38559511-BB39C054-A2B9-49FA-B9BB-EE621D279251Q38622440-C2CC0036-FC7A-44FF-9352-76F03EE18E72Q38818422-6DF7CB4C-1D22-45B0-8404-D0A19909EFD9Q38950892-56B93EA2-C293-40B5-B227-A7FF3F3B10E4Q39409371-9E935C15-43DC-46CB-B7B6-F8A6102DC0DFQ40595052-3BA1814E-5445-4EBD-8699-79458A1479AFQ40735084-1D80A352-2517-401E-B634-7534404903C9Q41551945-3BA205A8-410F-4A1F-A4D8-6A6C1E91B36AQ47115558-9349640C-5987-43F5-9631-FC867D3F5C2A
P2860
Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera®).
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Safety profile of recombinant ...... ipogene tiparvovec (Glybera®).
@en
type
label
Safety profile of recombinant ...... ipogene tiparvovec (Glybera®).
@en
prefLabel
Safety profile of recombinant ...... ipogene tiparvovec (Glybera®).
@en
P2093
P2860
P1476
Safety profile of recombinant ...... ipogene tiparvovec (Glybera®).
@en
P2093
Florence Salmon
Harald Petry
Konstantina Grosios
P2860
P356
10.1586/17512433.2014.852065
P407
P577
2013-11-25T00:00:00Z